QuidelOrtho Corporation heads into its Q1 2026 earnings report with short sellers at their most aggressive in months and options traders stacking downside protection — a setup shaped by a stock down 32% in a single month.
Short interest has become the defining feature of the positioning story. At 17.5% of the free float, it represents a meaningful and rising bet against the company. Bears added about 13% more shorts over the past month alone, and the position is now running near its highest levels of recent history. The ORTEX short score — which combines multiple bearish signals — clocked in at 62.8 on May 4, the firmest reading in the 10-day history available and well above neutral. Despite that pressure, borrow remains accessible: the cost to borrow is just 0.52% annualised, and availability is loose, meaning new short positions face no friction entering. The lending market is not pointing to any squeeze tension.
Options traders have shifted decisively defensive heading into the print. The put/call ratio hit 1.41 on Tuesday, more than one standard deviation above its 20-day average of 1.02. That tilt toward puts has persisted for over two weeks — the PCR crossed above 1.25 on April 22 and has not looked back — suggesting this is a considered positioning shift, not a one-day spike. The stock itself closed at $11.66 on May 5, down 6% on the day and off 32% for the month. Correlated peer fell 3.5% on the week and dropped nearly 5%, so broader health care equipment weakness provided context — but QDEL's drop has been sharper than either.
The analyst community has been moving in one direction: lower. UBS cut its price target from $30 to $17 on April 10 — slashing it by 43% while keeping a Neutral rating — the clearest sign that even non-bearish analysts are losing conviction on near-term recovery. The mean consensus target of $27 looks significantly above the current price at $11.66, implying over 100% return potential on paper, but that gap reflects how far and fast the stock has fallen rather than fresh optimism. The EV/EBITDA multiple of around 5x is cheap in isolation. The company carries $2.4 billion in net debt against an enterprise value near $3.4 billion, which limits the margin for disappointment if revenue misses. The last earnings print — Q4 2025 — produced an 18% one-day drop and an 18% five-day decline, establishing a pattern where misses have been punished hard.
One note of nuance: insiders have been receiving share awards and selling small tranches on the open market, all at very low dollar values and with significance scores of 1 out of 10. The net 90-day insider position is technically positive, but the transactions are routine award-and-sell patterns rather than conviction buying. They do not change the story.
Today's print is therefore less about whether QuidelOrtho can eventually recover and more about whether Q1 revenue and margin trends are stable enough to stop the target-cut cycle that has been accelerating since late 2024.
See the live data behind this article on ORTEX.
Open QDEL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
